Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CUR Neuralstem (CUR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Neuralstem Stock (NASDAQ:CUR) 30 days 90 days 365 days Advanced Chart Remove Ads Get Neuralstem alerts:Sign Up Key Stats Today's Range$0.64▼$0.6950-Day Range$0.67▼$1.5252-Week Range$1.10▼$13.78Volume68,883 shsAverage Volume236,278 shsMarket Capitalization$1.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Read More… Remove Ads Receive CUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuralstem and its competitors with MarketBeat's FREE daily newsletter. Email Address CUR Stock News HeadlinesAguas Da Curia Share Price (CUR.LS)November 25, 2023 | lse.co.ukXAUUSD:CUR Gold Spot PriceAugust 22, 2023 | seekingalpha.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 1, 2025 | Porter & Company (Ad)4 Biotech Stocks Under $10 Moving HigherJuly 20, 2023 | thestreet.comXPTUSD:CUR Platinum Spot PriceJune 28, 2023 | seekingalpha.comXAUUSD:CURMay 16, 2023 | seekingalpha.comNovAccess Global : Announces Fireside Chat with Board Member Perspectives - Marketscreener.comOctober 20, 2022 | marketscreener.comAnti-inflammatory compound supercharges stem cell stroke treatment - Yahoo NewsOctober 12, 2022 | news.yahoo.comSee More Headlines CUR Stock Analysis - Frequently Asked Questions How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.45) earnings per share (EPS) for the quarter. The business earned $0.01 million during the quarter. Neuralstem had a negative net margin of 39,417.64% and a negative trailing twelve-month return on equity of 170.51%. When did Neuralstem's stock split? Neuralstem's stock reverse split before market open on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Neuralstem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuralstem investors own include XOMA (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Turkcell Iletisim Hizmetleri A.S. (TKC), Idera Pharmaceuticals (IDRA), SELLAS Life Sciences Group (SLS) and ACADIA Pharmaceuticals (ACAD). Company Calendar Last Earnings8/14/2019Today3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CUR CIK1357459 Webwww.neuralstem.com Phone301-366-4841FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,930,000.00 Net Margins-39,417.64% Pretax MarginN/A Return on Equity-170.51% Return on Assets-110.16% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual Sales$260,000.00 Price / Sales5.56 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book0.10Miscellaneous Outstanding Shares2,100,000Free FloatN/AMarket Cap$1.45 million OptionableNot Optionable Beta1.81 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:CUR) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.